<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>Mail.com: Gilead Sciences, Inc.</title>
    <link>http://www.mail.com/companies/34006-gilead-sciences-inc.html</link>
    <description>Mail.com - the best personalized free web-based Email</description>
    <language>en</language>
    <dc:language>en</dc:language>
    <image>
      <title>Mail.com: Gilead Sciences, Inc.</title>
      <url>http://sec-s.uicdn.com/mail.com/2.28/img/mailcom_logo_rss.png</url>
      <link>http://www.mail.com/companies/34006-gilead-sciences-inc.html</link>
    </image>
    <item>
      <title>Drug companies forge partnerships with top schools</title>
      <link>http://www.mail.com/business/economy/1812008-drug-companies-forge-partnerships-with-top-schools.html</link>
      <description>ST. LOUIS (AP) — In their quest for the next big drug discovery, pharmaceutical companies are increasingly teaming up with some of the nation's top universities, recruiting campus scientists as partners and offering schools multimillion-dollar deals to work on experimental drugs in development. 
                   Big Pharma has long sought to profit from academia's innovati...</description>
      <pubDate>Thu, 10 Jan 2013 20:48:00 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/business/economy/1812008-drug-companies-forge-partnerships-with-top-schools.html</guid>
      <dc:date>2013-01-10T20:48:00Z</dc:date>
    </item>
  </channel>
</rss>

